Why GST rate revision may not help in the long term, impact of rising oil prices, USFDA observations for Indian pharma plants and mid-cap stock rally,.
Edited Highlighs
1:35 The GST Council has slashed tax rates for many items and just 50 items are there in the 28% slab
1:42 The problem has not been the taxation rates but the cumbersome filing process. The government seems to have missed the point
2:07 It can give a short term boost to some sector but the problem is more in terms of compliance rather than GST rates
3:18 The royal purge and power struggle in Saudi Arabia can have major repercussions for international oil prices which are already at a two year high
3:25 This can also affect international stock markets. More so if there is a conflict between Saudi Arabia and Iran
3:36 I think market valuations, despite doing well are not factoring in political issues
3:42 These political issues can disturb market valuations
4:01 This is despite global economy recovering and doing very well
4:17 USFDA observations for pharma major Lupin and other pharma companies
4:22 These are for major facilities such as Goa and Indore for Lupin
4:36 All this is not auguring well for the pharma sector in India. There is also the pricing pressure in the US. These will impact pharma stock valuations
4:53 The steps of the government to recapitalise banks should be helpful. Axis Bank is raising fresh capital. This will help the economy
5:32 The GDP may fall even further. Though there could be help from the low statistical base
5:51 The mid cap stock rally has become a frenzy. Stock valuations are multiplying and these are the types of scenarios when corrections seem round the corner
6:05 Long term investor in stocks should invest in a staggered manner
